RBC Capital Raises RVMD Price Target to $260
RBC Capital has maintained its Outperform rating on Revolution Medicines, Inc. with a revised price target of $260, a 42.85% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
RBC Capital raised its price target on Revolution Medicines, Inc. ($RVMD) to $260 from $259 on October 14, 2026, and rates the stock "Outperform".
Since the rating, $RVMD is down 8.0% to date (from the $193.52 close on Oct 14, 2026).
RVMD
Revolution Medicines, Inc.
Key Points
- On October 14, 2026, RBC Capital reiterated its Outperform rating on Revolution Medicines, Inc. with a target of $260, up from $259.
- RBC Capital's $260 price target implies 42.85% upside from Revolution Medicines, Inc.'s ($RVMD) current $182.01 share price.
- The stock recently traded at $182.01, which is about 30% below RBC's new target.
- Revolution Medicines is set to report earnings on November 4, 2026.
Get $RVMD trade alerts by text
We text you when insiders, Congress or big funds trade $RVMD. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
RBC Capital has reiterated its Outperform rating on Revolution Medicines, Inc. (NasdaqGS: RVMD) on October 14, 2026, setting a price target of $260. This is a slight increase from the previous target of $259.
The stock recently traded around $182.01, which is about 30% below RBC's updated target. This suggests that analysts at RBC see potential for significant upside in the stock price compared to its recent trading level.
RBC Capital vs. the S&P 500
Hypothetical returns from RBC Capital's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Revolution Medicines, Inc.
Several institutional investors have been active in Revolution Medicines recently. Blackrock Inc. holds 13,695,790 shares worth about $2.44 billion after growing its stake by 2,483,518 shares, a 22.1% increase. FMR, LLC added 3,736,136 shares to reach a total of 12,200,422 shares valued at approximately $2.17 billion, representing a 44.1% increase. Baker Bros. Advisors, LP also increased its holdings by 1,888,116 shares, totaling 11,443,357 shares worth about $2.04 billion.
Revolution Medicines, Inc. Stock Down 4.7%
As of October 16, 2026, Revolution Medicines shares are trading at $182.01. This price is considerably lower than RBC Capital's target of $260, indicating that analysts believe the stock has room to grow. The company operates in the biotechnology sector, focusing on developing targeted therapies for cancers driven by RAS mutations.
$RVMD price target
Revolution Medicines, Inc. daily closes and this analyst's $260 target. Not advice.
Recent Earnings
Revolution Medicines has not reported a profit recently, with a trailing twelve-month EPS of -$8.87. Its next earnings report is scheduled for November 4, 2026.
Insider Buying and Selling at Revolution Medicines, Inc.
Several insiders sold shares recently. Elizabeth M. Anderson, a Director, sold 10,143 shares valued at about $1.96 million on September 22, 2026. Officer Anthony Mancini sold 3,708 shares for approximately $743,285 on September 25, 2026. General Counsel Jeffrey Todd Cislini sold 765 shares at an average price of $207.32, totaling about $158,600, also on September 25, 2026. Officer Alan B. Sandler sold 6,309 shares valued at around $1.28 million on September 29, 2026.
Analysts Set New Price Targets
On October 14, 2026, RBC Capital maintained its Outperform rating on the stock with a new price target of $260, up from $259. Earlier, on October 8, RBC had also set a target of $259. Other analysts have been active too; B of A Securities maintained a Buy rating with a target of $265 on September 21, 2026, and Brookline Capital initiated coverage with a Buy rating and a target of $318 on September 28, 2026.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage company based in Redwood City, California. It focuses on developing innovative therapies for cancers that rely on RAS mutations. The company's research includes RAS(ON) inhibitors and companion inhibitors aimed at treating RAS-driven cancers.
Bottom Line
Investors should watch for Revolution Medicines' upcoming earnings report on November 4, 2026. RBC Capital's latest rating and target suggest confidence in the company's future performance despite recent insider selling.
Related Filing Alerts
Source: RBC Capital's rating change on $RVMD (Oct 14, 2026). Written by software, not financial advice. How we make alerts